Back to Search Start Over

Curcumin Formulations and Trials: What’s New in Neurological Diseases

Authors :
Gagliardi, S
Morasso, C
Stivaktakis, P
Pandini, C
Tinelli, V
Tsatsakis, A
Prosperi, D
Hickey, M
Corsi, F
Cereda, C
Gagliardi, Stella
Morasso, Carlo
Stivaktakis, Polychronis
Pandini, Cecilia
Tinelli, Veronica
Tsatsakis, Aristides
Prosperi, Davide
Hickey, Miriam
Corsi, Fabio
Cereda, Cristina
Gagliardi, S
Morasso, C
Stivaktakis, P
Pandini, C
Tinelli, V
Tsatsakis, A
Prosperi, D
Hickey, M
Corsi, F
Cereda, C
Gagliardi, Stella
Morasso, Carlo
Stivaktakis, Polychronis
Pandini, Cecilia
Tinelli, Veronica
Tsatsakis, Aristides
Prosperi, Davide
Hickey, Miriam
Corsi, Fabio
Cereda, Cristina
Publication Year :
2020

Abstract

Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the eects of curcumin on cognitive decline.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1308937216
Document Type :
Electronic Resource